Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Trial details
- Registry ID
- NCT02612311
- Phase
- Phase 3
The FDA approved Chlorambucil (Leukeran) on 18 Mar 1957.
Drug identity checked against registry records
Also recorded as Leukeran
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311 | TGTX | Phase 3 | Terminated | 2023-02-22Actual |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-08Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1957-03-18Day | Chlorambucil | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA010669", "applicant_as_listed_by_fda": "WAYLIS THERAP", "brand_names": ["LEUKERAN"], "active_ingredients": ["CHLORAMBUCIL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19570318", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |